华润双鹤(600062.SH)：羟钴胺注射液获得药物临床试验批准通知书

Core Viewpoint - China Resources Double Crane (600062.SH) has received the clinical trial approval notice from the National Medical Products Administration for Hydroxocobalamin Injection, indicating a significant step in the development of this treatment for metabolic disorders in children [1] Group 1 - The approved drug, Hydroxocobalamin Injection, is intended for the treatment of methylmalonic acidemia with or without homocystinuria in pediatric patients [1]